| Literature DB >> 29934472 |
Filippos Porichis1, Meghan G Hart1, Alexandra Massa1, Holly L Everett1, Antigoni Morou2, Jonathan Richard2, Nathalie Brassard2, Maxime Veillette2, Muska Hassan1, Ngoc Le Ly1, Jean-Pierre Routy3,4, Gordon J Freeman5,6, Mathieu Dubé2, Andrés Finzi2, Daniel E Kaufmann7,8.
Abstract
Immune exhaustion is an important feature of chronic infections, such as HIV, and a barrier to effective immunity against cancer. This dysfunction is in part controlled by inhibitory immune checkpoints. Blockade of the PD-1 or IL-10 pathways can reinvigorate HIV-specific CD4 T cell function in vitro, as measured by cytokine secretion and proliferative responses upon Ag stimulation. However, whether this restoration of HIV-specific CD4 T cells can improve help to other cell subsets impaired in HIV infection remains to be determined. In this study, we examine a cohort of chronically infected subjects prior to initiation of antiretroviral therapy (ART) and individuals with suppressed viral load on ART. We show that IFN-γ induction in NK cells upon PBMC stimulation by HIV Ag varies inversely with viremia and depends on HIV-specific CD4 T cell help. We demonstrate in both untreated and ART-suppressed individuals that dual PD-1 and IL-10 blockade enhances cytokine secretion of NK cells via restored HIV-specific CD4 T cell function, that soluble factors contribute to these immunotherapeutic effects, and that they depend on IL-2 and IL-12 signaling. Importantly, we show that inhibition of the PD-1 and IL-10 pathways also increases NK degranulation and killing of target cells. This study demonstrates a previously underappreciated relationship between CD4 T cell impairment and NK cell exhaustion in HIV infection, provides a proof of principle that reversal of adaptive immunity exhaustion can improve the innate immune response, and suggests that immune checkpoint modulation that improves CD4/NK cell cooperation can be used as adjuvant therapy in HIV infection.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29934472 PMCID: PMC6064609 DOI: 10.4049/jimmunol.1701551
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422